Pharma BD Deal Intelligence
Celgene's $9B all-cash acquisition of Juno Therapeutics gave it full control of JCAR017 (liso-cel), a CD19-directed CAR-T in pivotal trials for DLBCL, cementing Celgene's cell-therapy ambitions. The strategic goal was only partially achieved—liso-cel eventually reached market as Breyanzi, but well behind rival CAR-T therapies already approved.
Celgene Corporation to acquire Juno Therapeutics, Inc.
Celgene completes acquisition of Juno Therapeutics, Inc.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Celgene acquired Juno Therapeutics for approximately $9 billion ($87 per share in cash), gaining full ownership of JCAR017 (lisocabtagene maraleucel), a potentially best-in-class CD19-targeted CAR-T cell therapy in pivotal trials for diffuse large B-cell lymphoma.
80K US cases/yr · $18.0B Global NHL therapeutics
Non-Hodgkin lymphoma encompasses >60 subtypes of blood cancer. DLBCL and follicular lymphoma are most common. CAR-T, bispecifics, and novel targeted agents have expanded treatment options across subtypes.
Varies by subtype. Rituximab-based regimens backbone. CAR-T for R/R aggressive NHL. BTK inhibitors for MCL/CLL. Key players: Roche (Rituxan, Polivy), Gilead/Kite (Yescarta), BMS (Breyanzi), AbbVie (Imbruvica).
30K US cases/yr · $5.0B Global DLBCL therapeutics
DLBCL is the most common aggressive lymphoma. R-CHOP has been standard for decades. CAR-T therapy and bispecific antibodies have transformed relapsed/refractory disease.
First-line: R-CHOP or pola-R-CHP. R/R: CAR-T (axi-cel, liso-cel), bispecifics (glofitamab, epcoritamab). Key players: Roche (Polivy, Columvi), Gilead/Kite (Yescarta), BMS (Breyanzi), AbbVie/Genmab (Epkinly).
Celgene Corporation completed its acquisition of Juno Therapeutics Inc. for $9B.
FDA approval after Dec 31, 2020 CVR deadline terminated the agreement. Reflects financial performance following Celgene Corporation's $9B acquisition of Juno Therapeutics Inc..
Approved for relapsed/refractory LBCL with only 1% severe CRS. Regulatory step in Celgene Corporation's acquisition process for Juno Therapeutics Inc..
Approved for LBCL, SLL, follicular lymphoma, mantle cell lymphoma. Part of Celgene Corporation's $9B deal to acquire Juno Therapeutics Inc..
5 indications, favorable safety. Viable franchise but faces bispecific competition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Bristol-Myers Squibb Company (this deal) | 2018 | $9.0B | 68 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2018 deals · Celgene Corporation deals · Gene Therapy deals